SYNACT PHARMA
SynAct Pharma AB develops drugs for acute deterioration in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriatic arthritis - a form of acute joint disorder that affects approximately 30 percent of patients suffering from psoriasis. Preclinical studies show that AP1189 has a unique ability to both reduce inflammation and accelerate bleeding, which is expected to reduce joint damage that may occur after acute inflammation of the ... joints of the joints. AP1189 has the potential to be given in tablet form once a day. Results from a clinical phase I study are expected to be available during Q2 2018. The company intends to prepare for a first patient study in parallel with the completion of the phase I study. Assuming that AP1189 has proven safe and tolerable also in multiple dosing, the aim is to submit a clinical trial application (CTA) in patients with active arthritis (joint inflammation). After proof of concept has been shown in patients, the company intends to sign commercial agreements with one or more major pharmaceutical companies.
SYNACT PHARMA
Industry:
Biotechnology Health Care
Founded:
2012-01-01
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.synactpharma.com
Total Employee:
1+
Status:
Active
Contact:
+45 28 44 75 67
Total Funding:
71.43 K EUR
Technology used in webpage:
Google Tag Manager Content Delivery Network WordPress US Privacy User Signal Mechanism Cloudflare CDN Cloudflare Cloudflare JS CDN JS COVID-19 UNPKG
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Pandion Therapeutics
Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
SFA Therapeutics
SFA Therapeutics is a developer of drugs to treat chronic inflammatory diseases.
Current Advisors List
Board_member
2019-03-01
Current Employees Featured
Jeppe Ovli Ovlesen CEO @ SynAct Pharma
CEO
2014-01-01
Patrik Renblad Chief Financial Officer @ SynAct Pharma
Chief Financial Officer
2022-01-01
Thierry Duvauchelle Chief Medical Officer @ SynAct Pharma
Chief Medical Officer
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-12-12 | TXP Pharma | TXP Pharma acquired by SynAct Pharma | 136 M USD |
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - SynAct Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-07 | SynAct Pharma appoints Patrik Renblad as CFO |
| 2021-01-26 | SynAct Pharma names Thomas Boesen as Chief Operating Officer |
Official Site Inspections
http://www.synactpharma.com Semrush global rank: 1.9 M Semrush visits lastest month: 11.98 K
- Host name: 104.18.13.243
- IP address: 104.18.13.243
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "SynAct Pharma"
Organisation – SynAct Pharma
SynAct Pharma AB is a Swedish public company (Org. No: 559058-4826) listed on Nasdaq Stockholm, with its headquarters in Lund, Sweden. Research and...See details»
SynAct Pharma
SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology.See details»
Ownership Structure – SynAct Pharma
Feb 26, 2025 SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology.See details»
SynAct Pharma - Crunchbase Company Profile & Funding
SynAct Pharma AB develops drugs for acute deterioration in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriatic …See details»
SynAct Pharma AB (STO:SYNACT) Company Profile & Overview
Feb 28, 2025 Company profile for SynAct Pharma AB (STO:SYNACT) with a description, list of executives, contact details and other key facts.See details»
SynAct Pharma - LinkedIn
SynAct Pharma is a biotech company aiming at resolving inflammation by leveraging melanocortin biology. Our lead asset AP1189 is in phase 2 development for the treatment of rheumatoid …See details»
Synact Pharma - VentureRadar
ChemoCentryx, Inc. USA Acquired ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat …See details»
SynAct Pharma publishes Annual Report 2024 - Inderes
Apr 10, 2025 SynAct Pharma AB (publ) (“SynAct”) today publishes the Annual Report for the financial year 2024. The Annual Report is attached to this press release and available on the …See details»
SynAct Pharma - Overview, News & Similar companies
Jan 28, 2024 View SynAct Pharma (www.synactpharma.com) location in Skane, Sweden , revenue, industry and description. Find related and similar companies as well as employees …See details»
SynAct Pharma Overview | SignalHire Company Profile
SynAct Pharma is a biotech company aiming at resolving inflammation by leveraging melanocortin biology. Our lead asset AP1189 is in phase 2 development for the treatment of rheumatoid …See details»
SynAct Pharma publishes Annual Report 2024 - Placera.se
Apr 10, 2025 SynAct Pharma AB (publ) (“SynAct”) today publishes the Annual Report for the financial year 2024. The Annual Report is attached to this press release and available on the …See details»
SynAct Pharma publishes Annual Report 2023
Mar 26, 2024 SynAct Pharma AB (publ) (“SynAct”) today publishes the Annual Report for the financial year 2023. The Annual Report is attached to this press release and available on the …See details»
Investors – SynAct Pharma
Apr 10, 2025 SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology.See details»
SynAct Pharma publishes Annual Report 2024 | MarketScreener
Apr 10, 2025 SynAct Pharma AB (publ) (“SynAct”) today publishes the Annual Report for the financial year 2024. The Annual Report is attached to this press release and available on the …See details»
The Company in Brief – SynAct Pharma
SynAct Pharma AB is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a …See details»
SynAct Pharma - BIO International Convention | BIO
Jun 6, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services.See details»
Deep dive into SynAct Pharma’s new strategy - BioStock
Feb 8, 2024 BioStock reached out to SynAct Pharma's CEO Torbjørn Bjerke to learn more about the new strategic plan and insights from previous studiesSee details»
History – SynAct Pharma
Below is an overview of SynAct Pharma's history in brief. SynAct Pharma ApS was formed in 2012. SynAct Pharma AB, the Group's parent company, was...See details»
SynAct Pharma completes the acquisition of TXP Pharma
Jan 16, 2023 SynAct Pharma AB has today completed the acquisition of all shares in the Swiss-incorporated biotech company TXP Pharma AG that SynAct announced on December 12, …See details»
SynAct Pharma announces its 2024 strategic plan and milestones
Feb 2, 2024 SynAct Pharma AB (Nasdaq Stockholm: SYNACT), a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the …See details»